来自Dichapetalum longipetalum的二甲类三甲和它们的抗炎活性
Dong-Li Zhang1, Yue Wang1, Jing-Bo Liu1
1Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics, School of Pharmacy, Tianjin Medical University, Tianjin 300070, PR China.
Phytochemistry
|October 28, 2023
概括
研究人员从Dichapetalum longipetalum树枝中发现了五种新的二甲类型的三甲. 化合物1通过抑制巨细胞中氧化的产生,显示出有前途的抗炎活性.
科学领域:
- 植物化学 植物化学
- 自然产品 化学 化学
- 药理学 药理学是指药理学的学科.
背景情况:
- 迪沙佩塔 (Dichapetalum longipetalum) 是一种具有潜在药用功能的植物物种.
- 三类是众所周知的各种生物活动的一类天然化合物.
研究的目的:
- 从Dichapetalum longipetalum中分离和描述新的化合物.
- 评估隔离化合物的抗炎潜力.
主要方法:
- 对Dichapetalum longipetalum枝的植物化学研究.
- 使用高分辨率电喷射电离质谱法 (HR-ESIMS) 和核磁共振 (NMR) 谱法阐明结构.
- 通过单晶X射线晶体学确定化合物1的绝对配置.
- 在RAW264.7小鼠巨细胞中使用脂聚糖 (LPS) 诱导的氧化 (NO) 生产的体外抗炎试验.
主要成果:
- 确定了五种新的二甲类三甲类 (化合物1-5) 化合物.
- 所有化合物的化学结构都得到了阐明.
- 化合物1对LPS诱导的NO产生表现出显著的抑制活性,IC50值为2.09μM.
- 化合物1的绝对配置通过X射线结晶学得到证实.
结论:
- 对Dichapetalum longipetalum的植物化学分析产生了新的三类.
- 化合物1具有显著的抗炎性质,需要进一步研究.
- 这项研究扩大了对Dichapetalum天然产品及其生物活性的了解.
更多相关视频
13:18Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma
Published on: March 3, 2023
1.3K
07:50Author Spotlight: Integrating 2D-HPLC-MS and Molecular Networking in Natural Medicine Analysis
Published on: December 8, 2023
572
相关概念视频
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
192
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
192
01:19Antiasthma Drugs: Leukotriene Modifiers
324
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
324